Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oculis Holding AG (OCS : NSDQ)

• Company Description    Oculis Holding AG is a biopharmaceutical company which develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidate includes OCS-01, OCS-02 and OCS-05. Oculis Holding AG is based in Zug, Switzerland. Number of Employees: 49

• Price / Volume Information    Yesterday's Closing Price: $17.22 Daily Weekly Monthly 20 Day Moving Average: 13,321 shares Shares Outstanding: 43.66 (millions) Market Capitalization: $751.87 (millions) Beta: 0.26 52 Week High: $23.08 52 Week Low: $11.78 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.26% -5.01% 12 Week -11.60% -19.74% Year To Date 1.29% -9.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL BAHNHOFSTRASSE 7 - ZUG,V8 6300 CHE ph: 41-41-711-9325 fax: - ir@oculis.com http://www.oculis.com

• General Corporate Information    Officers Riad Sherif - Chief Executive Officer Anthony Rosenberg - Chairman Sylvia Cheung - Chief Financial Officer Christina Ackermann - Director Lionel Carnot - Director Peer Information Oculis Holding AG (CORR.) Oculis Holding AG (RSPI) Oculis Holding AG (CGXP) Oculis Holding AG (BGEN) Oculis Holding AG (GTBP) Oculis Holding AG (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H5870P102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 43.66 Most Recent Split Date: (:1) Beta: 0.26 Market Capitalization: $751.87 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 11.89% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.33 Price/Cash Flow: - Price / Sales: 848.60 EPS Growth vs. Year Ago Period: -5.36% vs. Previous Quarter: 23.38% Sales Growth vs. Year Ago Period: 16.61% vs. Previous Quarter: -0.32% ROE 06/30/25 - -90.31 03/31/25 - -92.95 12/31/24 - -93.14 ROA 06/30/25 - -67.85 03/31/25 - -70.03 12/31/24 - -69.42 Current Ratio 06/30/25 - 4.55 03/31/25 - 4.79 12/31/24 - 2.37 Quick Ratio 06/30/25 - 4.55 03/31/25 - 4.79 12/31/24 - 2.37 Operating Margin 06/30/25 - -13,958.12 03/31/25 - -13,788.70 12/31/24 - -12,750.27 Net Margin 06/30/25 - -13,958.12 03/31/25 - -13,788.70 12/31/24 - -12,750.27 Pre-Tax Margin 06/30/25 - -13,992.32 03/31/25 - -13,815.93 12/31/24 - -12,530.94 Book Value 06/30/25 - 3.97 03/31/25 - 4.14 12/31/24 - 1.91 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.01 03/31/25 - 0.00 12/31/24 - 0.01 Debt-to-Capital 06/30/25 - 0.50 03/31/25 - 0.49 12/31/24 - 1.17

Powered by Zacks Investment Research ©